Israel Active

Israeli biotech Neurim has signed marketing agreements for its new Rx PedPRM treatment for sleep disorders in children with autism spectrum disorders and neurogenetic diseases. Kuhnil will market Rx PedPRM in Korea; Aspen in Australia and New Zealand.

Israel’s BioSight has reported that in treating patients with its Astarabine leukemia treatment, three patients with late-stage leukemia achieved full remission to date. Good results were also reported for older patients over 80.

Israeli biotech Gamida Cell published positive results in its Phase I/II trial of NiCord, for the treatment of Sickle-Cell Disease (SCD). All the patients that completed the trial were free of SCD symptoms.

Israel’s Microbot develops miniature robots for cleaning drainage pipes in the body, for example in the urethra or the brain thereby removing the necessity for surgery to replace them. Microbot has just completed its merger into Nasdaq-listed US company Stem Cell.

Israeli startups took the top honors in the App Competition, during Medica, the world’s leading annual medical trade fair. UpRight won €2,000 for its app and device to optimize posture, Biop Medical came 2nd with its cervical cancer testing device.  TytoCare came 3rd with its telemedicine solution.

Anglo-Israel cardiovascular conference. Tiberias is hosting the 6th Anglo Israel Cardiovascular Symposium - a two-day international conference of notable cardiologists and heart surgeons from Israel and the UK. One of the symposium founders - Dr. Romeo Vecht – was previously the cardiologist for the King of Jordan.  

Shift managers from Israel’s emergency response organization United Hatzalah visited medical charity Yad Sarah’s Jerusalem headquarters to gain a better understanding of their operation.

I reported previously on the huge $25 million donation to help fund Magen David’s new underground blood services center in Ramle. The groundbreaking event for the state-of-the-art rocket-proof site took place on Nov 17.

Israeli charity for the disabled, Beit Issie Shapiro, organized an event at Google’s London campus in which Israeli firms explained their technology for empowering the disabled. This included the Sesame phone, robots for autistic kids and smartphone navigation of wheelchairs.

The SD-809 (deutetrabenazine) treatment by Israel’s Teva for Huntington disease has been approved by the US FDA.